Paper33657296
Diffuse Large B-Cell Lymphoma.
Sehn LH and 1 other. N Engl J Med, 2021. Cited by 1,002 papers, by iCite.
Cite this record
ConductScience Library. Diffuse Large B-Cell Lymphoma. Papers, record 33657296. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33657296
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Lymphoma, Large B-Cell, Diffuse | Major topic |
| Algorithms | |
| Combined Modality Therapy | |
| Humans | |
| Neoplasm Staging | |
| Prognosis | |
| Risk Factors | |
| Stem Cell Transplantation | |
| Transplantation, Autologous |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH |
Source NIH RePORTER
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 34107188 | Diffuse Large B-Cell Lymphoma. | https://conductscience.org/library/papers/34107188 |
Source PubMed
References81
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31868632 | Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. | Lancet | 2019 | https://conductscience.org/library/papers/31868632 | PubMed |
| 2 | 16754935 | Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16754935 | PubMed |
| 3 | 29713087 | Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. | Nat Med | 2018 | https://conductscience.org/library/papers/29713087 | PubMed |
| 4 | 31157579 | Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/31157579 | PubMed |
| 5 | 28774879 | Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. | Blood | 2017 | https://conductscience.org/library/papers/28774879 | PubMed |
| 6 | 27382104 | Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27382104 | PubMed |
| 7 | 30617197 | Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. | Blood | 2019 | https://conductscience.org/library/papers/30617197 | PubMed |
| 8 | 29414277 | Post-Transplantation Lymphoproliferative Disorders in Adults. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29414277 | PubMed |
| 9 | 33211842 | Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. | Blood | 2021 | https://conductscience.org/library/papers/33211842 | PubMed |
| 10 | 30380386 | CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30380386 | PubMed |
| 11 | 24264230 | An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. | Blood | 2014 | https://conductscience.org/library/papers/24264230 | PubMed |
| 12 | 12075054 | The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. | N Engl J Med | 2002 | https://conductscience.org/library/papers/12075054 | PubMed |
| 13 | 32888407 | Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. | Lancet | 2020 | https://conductscience.org/library/papers/32888407 | PubMed |
| 14 | 29672223 | Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29672223 | PubMed |
| 15 | 28426350 | Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28426350 | PubMed |
| 16 | 28862883 | Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28862883 | PubMed |
| 17 | 27382100 | CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27382100 | PubMed |
| 18 | 9647875 | Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. | N Engl J Med | 1998 | https://conductscience.org/library/papers/9647875 | PubMed |
| 19 | 32289277 | A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. | Cancer Cell | 2020 | https://conductscience.org/library/papers/32289277 | PubMed |
| 20 | 31498031 | Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/31498031 | PubMed |
Cited by747
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,002 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42972012 | The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma. | Leukemia | 2026 | https://conductscience.org/library/papers/42972012 | PubMed |
| 42939957 | Plasma IgG N-Glycosylation as a Novel Biomarker of Disease Severity and Prognosis in Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. | Biomedicines | 2026 | https://conductscience.org/library/papers/42939957 | PubMed |
| 42936799 | Myocardial Infarction with Non-obstructive Coronary Arteries; Diffuse Large B-Cell Lymphoma Presenting as an Acute Coronary Syndrome. | Arch Acad Emerg Med | 2026 | https://conductscience.org/library/papers/42936799 | PubMed |
| 42930590 | Baseline Tumor Transcriptional Features and Event-Free Survival After Anti-CD19 CAR T-Cell Therapy with Axicabtagene Ciloleucel in Large B-Cell Lymphoma: An Exploratory Reanalysis of the Randomized ZUMA-7 Trial. | Med Sci (Basel) | 2026 | https://conductscience.org/library/papers/42930590 | PubMed |
| 42928836 | CD20-Positive B-Cell Non-Hodgkin Lymphoma Associated With Recurrent Acute Pancreatitis, Bilateral Renal Lesions, and Retroperitoneal Lymphadenopathy. | Cureus | 2026 | https://conductscience.org/library/papers/42928836 | PubMed |
| 42910135 | Associations of Subcutaneous and Visceral Fat Areas with Progression-Free Survival in Patients with Diffuse Large B-Cell Lymphoma. | Int J Med Sci | 2026 | https://conductscience.org/library/papers/42910135 | PubMed |
| 42890318 | Zanubrutinib monotherapy in CD79B-mutated relapsed or refractory diffuse large B-cell lymphoma: A multicenter Phase 2 study. | Hemasphere | 2026 | https://conductscience.org/library/papers/42890318 | PubMed |
| 42889486 | Spatial immune ecosystems and therapy resistance in large B-cell lymphoma: from single-cell multi-omics to immunotherapy-matched validation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42889486 | PubMed |
| 42882397 | From Divergent Pathogenesis to Precision Medicine: The Road to Targeted Therapy in HIV-Associated and HIV-Unrelated Diffuse Large B-Cell Lymphoma. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42882397 | PubMed |
| 42882057 | Analysis of Treatment Patterns and Outcomes Among Patients with Third-Line or Later (3L+) Diffuse Large B-Cell Lymphoma (DLBCL) with Multiple Qualifying Index Dates Treated in the United States. | J Clin Med | 2026 | https://conductscience.org/library/papers/42882057 | PubMed |
| 42881024 | Comorbidity Burden and Prognosis in Patients Aged 80+ Years With Large B-Cell Lymphoma. | Clin Lymphoma Myeloma Leuk | 2026 | https://conductscience.org/library/papers/42881024 | PubMed |
| 42871809 | Therapeutic potential of oncolytic viruses in hematopoietic malignancies: from preclinical insights to clinical realities. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42871809 | PubMed |
| 42852632 | Resistance to covalent Bruton's tyrosine kinase inhibitors in diffuse large B‑cell lymphoma: Molecular mechanisms and therapeutic implications (Review). | Int J Oncol | 2026 | https://conductscience.org/library/papers/42852632 | PubMed |
| 42813078 | Primary Diffuse Large B-cell Lymphoma of the Urinary Bladder: A Case Report and Narrative Review of Treatment Modalities and Clinical Outcomes. | Cureus | 2026 | https://conductscience.org/library/papers/42813078 | PubMed |
| 42812805 | Tracheostomy Before Polatuzumab Vedotin-Containing Therapy for Airway-Threatening Cervical Diffuse Large B-Cell Lymphoma: A Case Report of Two Patients. | Case Rep Hematol | 2026 | https://conductscience.org/library/papers/42812805 | PubMed |
| 42801263 | Diffuse Large B-Cell Lymphoma Presenting as an Infiltrative Masticator Space Lesion Mimicking Inflammatory Disease: A Case Report. | Cureus | 2026 | https://conductscience.org/library/papers/42801263 | PubMed |
| 42798844 | Macrophage phagocytosis checkpoints in DLBCL immunotherapy: an evidence-maturity framework from CD47 to CD200. | Front Oncol | 2026 | https://conductscience.org/library/papers/42798844 | PubMed |
| 42795255 | Late-Onset Neutropenia and Hypogammaglobulinemia After Dose-Adjusted R-EPOCH in Unfavorable Diffuse Large B-Cell Lymphoma. | Life (Basel) | 2026 | https://conductscience.org/library/papers/42795255 | PubMed |
| 42793820 | Is There a Tumor Proportion Score Threshold at Which Tumor-Cell PD-L1 Adds Prognostic Information Beyond the International Prognostic Index in Large B-Cell Lymphoma? | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42793820 | PubMed |
| 42782785 | Establishment of Patient-Derived Xenotransplant and Cell Line Models for Canine B-Cell Lymphoma. | Cells | 2026 | https://conductscience.org/library/papers/42782785 | PubMed |
Genes47
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33657296
GET https://conductscience.org/api/papers/v1/33657296/references?page=2